Disseminated Fusarium Infections in Patients Receiving Posaconazole Prophylaxis: A Report of 2 Patients and Brief Review of the Literature
John Byrne Fournier1, Vinod Thomas1, Catherine Breen1, Jonathan Cannella1, Douglas Heiner1, Todd Roberts1 & Gail Skowron1 Show affiliations
- M.D.Roger Williams Medical Center/Boston University School of Medicine, United States
American Journal of Infectious Diseases, Volume 11, Issue 4, pp. 113–116 · doi.org/10.3844/ajidsp.2015.113.116
Abstract
Fusarium is a filamentous fungi that has emerged as a frequent cause of invasive infections in immunocompromised patients. Dermatologists often play a critical role in diagnosing fusariosis, as greater than 70% of patients with disseminated infections have cutaneous involvement, and microbiologic evaluation of skin specimens provides the diagnosis in the majority of cases. Second-generation triazoles are typically the most effective medications in treating invasive Fusarium infections, and we discuss the benefits of using these medications, as well as detail the side effects of these therapeutic agents.
Licence and reuse
Open access. This article is licensed under a Creative Commons Attribution 3.0 Licence (CC BY 3.0), as printed on the article, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original authors and the source. No permission is needed.
How to reuse this articleResponses (0)
About this article
Fournier, J. B., Thomas, V., Breen, C., Cannella, J., Heiner, D., Roberts, T. & Skowron, G. (2015). Disseminated Fusarium Infections in Patients Receiving Posaconazole Prophylaxis: A Report of 2 Patients and Brief Review of the Literature. American Journal of Infectious Diseases, 11(4), 113–116. https://doi.org/10.3844/ajidsp.2015.113.116
- Licence
- CC BY 3.0
- Issue
- Volume 11, Issue 4
- Policies
- Editorial independenceUse of generative AIData availabilityAppeals and complaints
- Version
- Version of record
